Finally, the combined utilization of serum Gal-3 levels and Gal-3 expression in placenta samples to evaluate the risk for hypertensive disorders or preeclampsia was not feasible, thereby limiting the clinical applicability of our conclusions. This evidence concerns the gene LGALS3 and preeclampsia.